CN107998376A - The applications of CD42b in treatment medication for treating pyemia is prepared and combinations thereof - Google Patents
The applications of CD42b in treatment medication for treating pyemia is prepared and combinations thereof Download PDFInfo
- Publication number
- CN107998376A CN107998376A CN201711464264.2A CN201711464264A CN107998376A CN 107998376 A CN107998376 A CN 107998376A CN 201711464264 A CN201711464264 A CN 201711464264A CN 107998376 A CN107998376 A CN 107998376A
- Authority
- CN
- China
- Prior art keywords
- cd42b
- cooled
- dried powder
- freeze
- freeze dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses the application of CD42b or its fragment in preparation is used to treat medication for treating pyemia, which has certain pyemic effect for the treatment of.The invention also discloses pharmaceutical composition and its freeze dried powder containing CD42b, said composition and its freeze dried powder effectively mitigate septicopyemia symptom, and new research direction is provided for treatment pyemia field.
Description
Technical field
The invention belongs to treat the technical field of inflammatory conditions, and in particular to CD42b is in treatment medication for treating pyemia is prepared
Application and combinations thereof.
Background technology
Pyemia (Sepsis) is common complication after severe trauma, shock and infection, and further development can cause purulence
Toxicogenic shock, multiple organ dysfunction syndrome (MODS), even if high on basis and clinic study and Intensive Care Therapy means
The modern times of development are spent, clinical treatment still produces little effect, and the death rate remains high！Pyemia is inflammatory reaction and Activated Coagulation
Important stimulus factor, there are obvious cross reaction between Activated Coagulation and inflammatory reaction.
Research shows, during platelet activation participates in coagulation system activation, the membrane glycoprotein and regulatory factor on its surface
Play very crucial effect.Wherein early-stage study is found, membrane glycoprotein CD42b, which has, blocks pyemic effect, therefore urgently
A kind of effective dose need to be researched and developed treats pyemic autologous drug.
The content of the invention
In view of the problems of the above-mentioned prior art, the purpose of the present invention is to propose to a kind of CD42b to prepare treatment septicopyemia
Application in disease drug.The CD42b has certain pyemic effect for the treatment of.
The purpose of the present invention will be achieved by the following technical programs：
CD42b or its fragment are preparing the application in being used to treat medication for treating pyemia.
Above-mentioned application, wherein, the medicine is oral drugs.
Above-mentioned application, wherein, the CD42b is formulated into including forming medicine in one or more excipient or stabilizer
Compositions.
Above-mentioned application, wherein, described pharmaceutical composition is freeze-dried powder form.
It is a further object to provide a kind of pharmaceutical composition containing CD42b.Said composition can effectively subtract
Light septicopyemia symptom.
One kind is used to treat pyemic pharmaceutical composition, and described pharmaceutical composition includes CD42b or its fragment, Yi Zhonghuo
A variety of excipient or stabilizer.
One kind is prepared into freeze dried powder according to aforementioned pharmaceutical compositions.
Above-mentioned freeze dried powder, wherein, freezed and be made by the component of following parts by weight：10-28 parts of CD42b or its fragment,
400-800 parts of excipient, 1-1.5 parts of stabilizer, 9170-9590 parts of water for injection.
Above-mentioned freeze dried powder, wherein, the excipient is one kind or its combination in mannitol, gelatin or sucrose；Institute
Stabilizer is stated as one kind in glutathione, serine or sucrose or its combination.
A kind of preparation method of freeze dried powder, includes the following steps：Membrane glycoprotein, excipient, stabilizer are dissolved in note
Penetrate and use water, mix, filter, packing, precooling, vacuum drying, to obtain the final product.
A kind of preparation method of above-mentioned freeze dried powder, wherein, the precooling includes the following steps：It is cooled to 4 DEG C, it is cold
1h-2h is hidden, is cooled to 0 DEG C~-10 DEG C, freezes 2h~3h；- 25 DEG C~-30 DEG C are cooled to, freezes 1h~3h；It is cooled to -45 DEG C
~55 DEG C, freeze 2h~4h.
Compared with prior art, a kind of CD42b provided by the invention prepare treat medication for treating pyemia in application and its
Composition, what is reached has the technical effect that：The CD42b of the present invention has treatment pyemia, and is prepared into medicine, is taken for human body
With providing new research direction for treatment pyemia field；Freeze dried powder prepared by the present invention is suitable for oral, you can effectively
Ground mitigates septicopyemia symptom.
Below just in conjunction with the embodiments, the embodiment of the present invention is described in further detail, so that technical solution is more
It should be readily appreciated that, grasp.
Embodiment
Below by specific embodiment, the present invention will be described, but the present invention is not limited thereto.In following embodiments
The experimental method, is conventional method unless otherwise specified；The reagent and material, unless otherwise specified, can be from business
Approach obtains, example below and the scope of the claims for being not used to the limitation present invention, all equivalence enforcements without departing from carried out by the present invention
Or change, it is intended to be limited solely by the scope of this patent.
Embodiment 1
CD42b freeze dried powder formulas
CD42b 1.2g, mannitol 45g, glutathione 0.15g, water for injection 953.65g.
Preparation method：
By CD42b 1.2g, mannitol 45g, glutathione 0.15g is dissolved with appropriate water for injection, continues to add water for injection
To 1000g, 0.22 μm of membrane filtration is degerming, is sub-packed in 1ml/ branch in cillin bottle；
Cillin bottle after packing is subjected to precooling：4 DEG C are first cooled to, refrigerates 1h, is cooled to 0 DEG C, freezes 2h；Cooling
To -25 DEG C, 1h is freezed；Be cooled to -45 DEG C, freeze 2h, to obtain the final product；
Cillin bottle after precooling is dried in vacuo, to obtain the final product.Wherein, the CD42b in the present embodiment can be selected its fragment and replace
Generation.
Embodiment 2
CD42b freeze dried powder formulas
CD42b 1g, gelatin 40g, serine 0.1g, water for injection 958.9g.
Preparation method：
By CD42b 1g, gelatin 40g, serine 0.1g is dissolved with appropriate water for injection, continues to inject water to
1000g, 0.22 μm of membrane filtration is degerming, is sub-packed in 1ml/ branch in cillin bottle；
Cillin bottle after packing is subjected to precooling：4 DEG C are first cooled to, refrigerates 1.5h, is cooled to -2 DEG C, freezes 2.5h；
- 25 DEG C DEG C are cooled to, freezes 1h；Be cooled to -48 DEG C, freeze 2.5h, to obtain the final product；
Cillin bottle after precooling is dried in vacuo, to obtain the final product.
Embodiment 3
CD42b freeze dried powder formulas
CD42b 1.5g, sucrose 61g, serine 0.12g, water for injection 937.38g.
Preparation method：
By CD42b 1.5g, sucrose 61g, serine 0.12g is dissolved with appropriate water for injection, continues to inject water to
1000g, 0.22 μm of membrane filtration is degerming, is sub-packed in 1ml/ branch in cillin bottle；
Cillin bottle after packing is subjected to precooling：4 DEG C are first cooled to, refrigerates 1h, is cooled to -8 DEG C, freezes 2h；Cooling
To -28 DEG C, 2h is freezed；Be cooled to -50 DEG C, freeze 3h, to obtain the final product；
Cillin bottle after precooling is dried in vacuo, to obtain the final product.
Embodiment 4
CD42b freeze dried powder group of formula
CD42b 1.0g, sucrose 60g, gelatin 12g, serine 0.13g, water for injection 926.87g.
Preparation method：
CD42b 1.0g, sucrose 60g, gelatin 12g, serine 0.13g are dissolved with appropriate water for injection, continues filling and penetrates
With water to 1000g, 0.22 μm of membrane filtration is degerming, is sub-packed in 1ml/ branch in cillin bottle；
Cillin bottle after packing is subjected to precooling：4 DEG C are first cooled to, refrigerates 2h, is cooled to -10 DEG C, freezes 3h；Cooling
To -25 DEG C, 3h is freezed；Be cooled to -55 DEG C, freeze 4h, to obtain the final product；
Cillin bottle after precooling is dried in vacuo, to obtain the final product.
Embodiment 5
CD42b freeze dried powder formulas
CD42b 1.4g, sucrose 48g, glutathione 0.12g, water for injection 950.48g.
By CD42b1.4g, sucrose 48g, glutathione 0.12g is dissolved with appropriate water for injection, continues to inject water to
1000g, 0.22 μm of membrane filtration is degerming, is sub-packed in 1ml/ branch in cillin bottle；
Cillin bottle after packing is subjected to precooling：4 DEG C are first cooled to, refrigerates 1h, is cooled to -3 DEG C, freezes 2h；Cooling
To -28 DEG C, 1h is freezed；Be cooled to -45 DEG C, freeze 4h, to obtain the final product；
Cillin bottle after precooling is dried in vacuo, to obtain the final product.
Control group 1
CD42b 0.8g, mannitol 45g, glutathione 0.15g, water for injection 954.05g.
By CD42b 0.8g, mannitol 45g, glutathione 0.15g is dissolved with appropriate water for injection, continues to add water for injection
To 1000g, 0.22 μm of membrane filtration is degerming, is sub-packed in 1ml/ branch in cillin bottle；
Cillin bottle after packing is subjected to precooling：4 DEG C are first cooled to, refrigerates 1h, is cooled to -3 DEG C, freezes 2h；Cooling
To -28 DEG C, 1h is freezed；Be cooled to -45 DEG C, freeze 4h, to obtain the final product；
Cillin bottle after precooling is dried in vacuo, to obtain the final product.
Control group 2
CD42b 0.1g, mannitol 45g, glutathione 0.15g, water for injection 954.75g.
By CD42b 0.1g, mannitol 45g, glutathione 0.15g is dissolved with appropriate water for injection, continues to add water for injection
To 1000g, 0.22 μm of membrane filtration is degerming, is sub-packed in 1ml/ branch in cillin bottle；
Cillin bottle after packing is subjected to precooling：4 DEG C are first cooled to, refrigerates 1h, is cooled to -45 DEG C, freezes 4h, i.e.,
；
Cillin bottle after precooling is dried in vacuo, to obtain the final product.
Test example
Experimental procedure：
Material：SPF grades of SD male mices, weight 20 ± 2g, is divided into 9 groups by 90, every group 10, be respectively normal group,
Model group, embodiment 1-5 groups, control group 1-2.
Normal group is fed for chow diet, gives distilled water 0.1ml/20g；
Model group, embodiment 1-5 groups, control group 1-2 are first 2 days intraperitoneal injection LPS 40mg/kg, are opened within subsequent 3rd day
Beginning, model group continues to give distilled water 0.1ml/20g in 5 days,；
CD42b that embodiment 1-5 groups, control group 1-2 start to give for lasting 5 days its correspondence preparation on the 3rd day is freeze-dried
0.1ml/20g。
First 3 days it is every 12 it is small when mouse of observation state and activity, latter 5 days it is every 6 it is small when observe the state of a mouse
And activity, and count the survival rate of every group of mouse.It the results are shown in Table 1.
The freeze-dried pyemic influences on LPS inductions of 1 CD42b of table
After when LPS intraperitoneal injections 12 are small, 90% mouse appearance is slow in reacting, and activity and feed are reduced, and secretion increases
Symptom；15 it is small when after, all mouse occur it is slow in reacting, activity and feed reduce, the symptom that secretion increases；48 is small
When, then the above-mentioned symptom of mouse aggravates, then the success using the state of mouse at this time as model manufacturing.
CD42b has pyemic effect for the treatment of, and CD42b freeze dried powders treatment LPS prepared by the present invention as shown in Table 1
The pyemic effect of inducing mouse has significant difference, has certain therapeutic effect；The optimum weight of CD42b in the present invention
Part be 10-28 part, and optimal precooling condition refrigerates 1h-2h, is cooled to 0 DEG C~-10 DEG C to be cooled to 4 DEG C, freeze 2h~
3h；- 25 DEG C~-30 DEG C are cooled to, freezes 1h~3h；- 45 DEG C~-55 DEG C are cooled to, freezes 2h~4h.
Some preferred embodiments of the present invention have shown and described in described above, but as previously described, it should be understood that the present invention
Be not limited to form disclosed herein, be not to be taken as the exclusion to other embodiment, and available for various other combinations,
Modification and environment, and above-mentioned teaching or the technology or knowledge of association area can be passed through in the scope of the invention is set forth herein
It is modified., then all should be in this hair and changes and modifications made by those skilled in the art do not depart from the spirit and scope of the present invention
In the protection domain of bright appended claims.
Claims (10)
1.CD42b or its fragment are preparing the application in being used to treat medication for treating pyemia.
2. according to the application described in claim 1, it is characterised in that the medicine is oral drugs.
3. according to the application described in claim 2, it is characterised in that the CD42b is formulated into including one or more figurations
Pharmaceutical composition is formed in agent or stabilizer.
4. according to the application described in claim 3, it is characterised in that described pharmaceutical composition is freeze-dried powder form.
5. one kind is used to treat pyemic pharmaceutical composition, it is characterised in that described pharmaceutical composition includes CD42b or its piece
Section, one or more excipient or stabilizer.
6. a kind of pharmaceutical composition according to claim 5 is prepared into freeze dried powder.
7. freeze dried powder according to claim 6, it is characterised in that freezed and be made by the component of following parts by weight：CD42b
Or 10-28 parts of its fragment, 400-800 parts of excipient, 1-1.5 parts of stabilizer, 9170-9590 parts of water for injection.
8. freeze dried powder according to claim 7, it is characterised in that the excipient is in mannitol, gelatin or sucrose
One kind or its combination；The stabilizer is one kind or its combination in glutathione, serine or sucrose.
9. a kind of preparation method of freeze dried powder, it is characterised in that include the following steps：By membrane glycoprotein, excipient, stabilizer
Water for injection is dissolved in, is mixed, is filtered, packing, precooling, vacuum drying, to obtain the final product.
10. the preparation method of a kind of freeze dried powder according to claim 9, it is characterised in that the precooling is included such as
Lower step：4 DEG C are cooled to, refrigerates 1h-2h, is cooled to 0 DEG C~-10 DEG C, freezes 2h~3h；It is cooled to -25 DEG C~-30 DEG C, it is cold
Freeze 1h~3h；- 45 DEG C~-55 DEG C are cooled to, freezes 2h~4h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711464264.2A CN107998376A (en) | 2017-12-28 | 2017-12-28 | The applications of CD42b in treatment medication for treating pyemia is prepared and combinations thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711464264.2A CN107998376A (en) | 2017-12-28 | 2017-12-28 | The applications of CD42b in treatment medication for treating pyemia is prepared and combinations thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107998376A true CN107998376A (en) | 2018-05-08 |
Family
ID=62062267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711464264.2A Pending CN107998376A (en) | 2017-12-28 | 2017-12-28 | The applications of CD42b in treatment medication for treating pyemia is prepared and combinations thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107998376A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108042792A (en) * | 2017-12-28 | 2018-05-18 | 南京东诺医药科技开发有限责任公司 | The applications of CD61 in treatment medication for treating pyemia is prepared and combinations thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284568A (en) * | 1999-08-13 | 2001-02-21 | 杨梦甦 | Disease detecting method utilizing leucocyte disserentiating antigen gene chip |
| CN101020048A (en) * | 2007-02-12 | 2007-08-22 | 广东天普生化医药股份有限公司 | Pyemia treating medicine composition |
| WO2017083599A1 (en) * | 2015-11-12 | 2017-05-18 | Goetzl Edward J | Platelet biomarkers and diagnostic methods for vascular diseases |
| CN108042792A (en) * | 2017-12-28 | 2018-05-18 | 南京东诺医药科技开发有限责任公司 | The applications of CD61 in treatment medication for treating pyemia is prepared and combinations thereof |
-
2017
- 2017-12-28 CN CN201711464264.2A patent/CN107998376A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284568A (en) * | 1999-08-13 | 2001-02-21 | 杨梦甦 | Disease detecting method utilizing leucocyte disserentiating antigen gene chip |
| CN101020048A (en) * | 2007-02-12 | 2007-08-22 | 广东天普生化医药股份有限公司 | Pyemia treating medicine composition |
| WO2017083599A1 (en) * | 2015-11-12 | 2017-05-18 | Goetzl Edward J | Platelet biomarkers and diagnostic methods for vascular diseases |
| CN108042792A (en) * | 2017-12-28 | 2018-05-18 | 南京东诺医药科技开发有限责任公司 | The applications of CD61 in treatment medication for treating pyemia is prepared and combinations thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘庆新等人: "高血压脑出血患者血小板CD62p和CD42b的表达及其与脑水肿形成的关系", 《中华急诊医学杂志》 * |
| 孙运秀等人: "血小板膜糖蛋白CD61、CD62P在小鼠脓毒症炎性反应中的调控作用", 《中华实验外科杂志》 * |
| 林孟相等人: "脓毒症患者血小板膜糖蛋白CD62p和CD63的表达及其临床意义", 《中国呼吸与危重监护杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108042792A (en) * | 2017-12-28 | 2018-05-18 | 南京东诺医药科技开发有限责任公司 | The applications of CD61 in treatment medication for treating pyemia is prepared and combinations thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101512495B1 (en) | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction | |
| CN102885857A (en) | Extraction method of periplaneta americana extract for treating peptic ulcer | |
| US10314806B2 (en) | Preparation containing chlorogenic acid crystal form and use thereof | |
| WO2016095503A1 (en) | Application of derivative of clostridium ghonii | |
| KR101117861B1 (en) | A forsythoside injection and preparation thereof | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN106668832A (en) | Application of polypeptide in preparing medicine for treating enterovirus infection | |
| CN106074465A (en) | Cannabinol compounds application in preparation treatment gouty arthritis medicine | |
| Li et al. | Functional recovery after acute intravenous administration of human umbilical cord mesenchymal stem cells in rats with cerebral ischemia-reperfusion injury | |
| CN107998376A (en) | The applications of CD42b in treatment medication for treating pyemia is prepared and combinations thereof | |
| CN104628657A (en) | Class of compounds for treating ischemic brain damage and purpose thereof | |
| CN108042792A (en) | The applications of CD61 in treatment medication for treating pyemia is prepared and combinations thereof | |
| CN115105509A (en) | Application of dipyridamole in preparation of medicine for preventing and/or treating necrotizing enterocolitis | |
| CN106794199B (en) | Agent for promoting Tau protein production and therapeutic/prophylactic agent for diseases caused by deficiency of Tau protein | |
| CN103784905A (en) | Traditional Chinese medicine powder for treating swine edema and preparation method thereof | |
| JPWO2015156409A1 (en) | Anticancer agent and side effect reducing agent | |
| CN103830255A (en) | Application of paeoniflorin in preparation of medicines for treating cerebrovascular diseases | |
| CN108836975B (en) | New application of multinoside | |
| KR101772954B1 (en) | A anticancer pharmaceutical composition comprising herbal mixture extract of akebia quinata seed extract and panax ginseng, and lipopolysacharide | |
| CN105963287B (en) | Compound and its medical usage | |
| CN108567768B (en) | Medical application of p- [ (dipropylamino) sulfonyl ] benzoic acid | |
| WO2006029550A1 (en) | Hemostatic mistura of ipomoea balatas leaves, methods of preparation and use thereof | |
| CN1895314A (en) | A lyophilized powder for injection containing Notoginseng radix total saponin with good appearance and shatter resistance, and its preparation method | |
| UA102645C2 (en) | Tableted agent based on porcine cryo-dried skin | |
| CN1228081C (en) | Combination of medicinal preparation of having antivirus function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180508 |
|
| RJ01 | Rejection of invention patent application after publication |